Risk Factors for Lateral Neck Recurrence of N0/N1a Papillary Thyroid Cancer
Current guidelines advocate no prophylactic dissection of the lateral neck compartment for papillary thyroid carcinoma (PTC) without clinical evidence of lateral neck metastasis (cN1b). However, lateral neck recurrence can affect patient treatment outcomes and quality of life. Therefore, this study examined the risk factors for lateral neck recurrence after the definitive treatment of PTC without cN1b.
The study enrolled 1928 consecutive patients who underwent total thyroidectomy between 2006 and 2012 for PTC without cN1b. Logistic regression analysis was used to identify the relationship of clinicopathologic factors with lateral neck recurrence. Uni- and multivariate Cox-proportional hazards regression analyses were used to identify factors predictive of lateral neck recurrence-free survival (LRFS).
During a median follow-up period of 94 months (range, 24–133 months), lateral neck recurrence occurred in 47 patients (2.4%). Binary logistic regression showed that tumor size (>2 cm), multifocality, clinical central neck metastasis (cN1a), number of positive lymph nodes (LNs, >5), and LN ratio (>0.5) were significantly associated with lateral neck recurrence (P < 0.05). Multivariate analyses showed that multifocality (hazards ratio [HR], 2.338; 95% confidence interval [CI], 1.126–4.858; P = 0.023), cN1a (HR, 5.301; 95% CI, 2.416–11.630; P < 0.001), LN ratio (HR, 2.628; 95% CI, 1.228–5.626; P = 0.013), extranodal extension (HR, 2.570; 95% CI, 1.063–6.213; P = 0.036), and MACIS (distant metastasis, patient age, completeness of resection, local invasion and tumour size) score (HR, 2.513; 95% CI, 1.211–5.216; P = 0.013) were independent factors for LRFS.
Lateral neck recurrence after thyroidectomy is predicted by the clinicopathologic factors of multifocality, cN1a, LN ratio, extranodal extension, and MACIS score in N0/N1a PTC patients.
This study was supported by a grant (No. 2015R1A2A1A15054540) from the Basic Science Research Program through the National Research Foundation of Korea (NRF), Ministry of Science, ICT, and Future Planning, and a grant (No. HI15C2920) from the Korean Health Technology R&D Project through the Korea Health Industry Development Institute, Ministry of Health & Welfare, Seoul, Republic of Korea (J.-L. Roh).
The authors have declared no conflict of interest.
- 7.Viola D, Materazzi G, Valerio L, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab. 2015;100:1316–24.CrossRefPubMedGoogle Scholar
- 8.Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. The American Joint Committee for Cancer (AJCC) Cancer Staging Manual. 7th ed. Springer, New York, NY, 2010, pp 87–96.Google Scholar
- 19.Kruijff S, Aniss AM, Chen P, et al. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma. Surgery. 2013;154:1337–44; discussion 1344–5.Google Scholar
- 32.Pereira JA, Jimeno J, Miquel J, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery. 2005;138:1095–100, discussion 1100–1091.Google Scholar